Recent Company News

• 05:49 AM ET Aug 12, 2025
  

  Pfizer, Astellas Pharma's Phase 3 EV-303 clinical trial meet primary and secondary endpoints

• 10:41 PM ET Jul 30, 2025
  

  StreetAccount Summary - Trading higher/lower: Japan mid-day

• 07:14 PM ET Jul 30, 2025
  

  Japan post-close earnings highlights:

• 02:38 AM ET Jul 30, 2025
  

  Astellas Pharma reports Q1 core profit ¥104.72B vs year-ago ¥67.15B and FactSet ¥49.71B (¥1488.0000, 0)

• 10:57 AM ET Jul 29, 2025
  

  Glass Lewis, ISS vs Texas; new corporate data collection and reporting tools among ESG products & ratings highlights Jun-Jul

• 08:58 AM ET Jul 10, 2025
  

  StreetAccount Sector Summary - Healthcare Pre-Market

• 06:49 AM ET Jul 10, 2025
  

  Pfizer and Astellas (4503.JP) announce topline results from the overall survival (OS) analysis from the Phase 3 EMBARK study ($25.56, 0.00)

• 07:36 PM ET Jul 09, 2025
  

  Astellas Pharma reports preliminary Q1 U.S. sales of IZERVAY $110M ( ¥15.9B) (¥1386.0000, 0)

• 07:44 PM ET Jul 07, 2025
  

  Astellas Pharma downgraded to neutral from buy at Mizuho Securities (¥1382.0000, 0)

• 10:47 AM ET Jun 24, 2025
  

  CDP ocean questions; ESMA ratings rule consultation; GRI Sustainable Taxonomy among ESG products & ratings highlights May-Jun